IRBM

IRBM is an innovative contract research organization working across all aspects of drug discovery and early development for different modalities – small molecules, peptides, and antibodies. We foster collaborations with organizations from the pharmaceutical, biotech and academic sectors to accelerate drug discovery from target validation and hit identification to candidate nomination. Our 200 plus-strong, multidisciplinary teamwork at a state-of-the-art R&D facility near Rome where projects are carried out “under one roof” enabling rapid cycle times and close integration of the scientific teams. IRBM’s scientists have discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing. The company was founded in 2010, as a spin-off from Merck & Co. Now in our 14th year as an independent research organisation, we have laid the foundations to become a global centre for excellence in all aspects of drug discovery and early development.
Our integrated and standalone capabilities include HTS, strong medicinal chemistry and peptide chemistry, CADD, in vitro biology, DMPK, phage display, biomarker development and NMR.